For people living with type 1 or type 2 diabetes, managing blood sugar levels with insulin is a daily reality. Yet, even with diligent monitoring and insulin use, achieving stable glucose control can be a constant challenge, especially after meals. Those frustrating post-meal spikes can feel unpredictable and difficult to manage. This is where a unique, adjunctive therapy called SymlinPen (pramlintide acetate) can play a supportive role.

SymlinPen is not insulin, nor is it a replacement for it. Instead, it is an injectable prescription medication that works alongside insulin to improve glucose control. It belongs to a class of drugs known as amylin analogs, meaning it is a synthetic version of a natural hormone called amylin. In people without diabetes, amylin and insulin are released together by the pancreas to manage blood sugar. SymlinPen is designed for patients who use mealtime insulin but still struggle to reach their blood sugar targets, offering another tool to help smooth out the peaks and valleys of daily glucose management.

What does SymlinPen do?

SymlinPen is approved by the U.S. Food and Drug Administration (FDA) as an add-on treatment for adults with either type 1 or type 2 diabetes who use mealtime insulin. Its primary purpose is to improve glycemic control, particularly after eating.

By adding SymlinPen to their insulin regimen, patients may experience:

• Reduced Post-Meal Blood Sugar Spikes: It helps to prevent the sharp rise in glucose that can occur after eating a meal.
• Lower Hemoglobin A1c Levels: By improving overall glucose control, it can help lower A1c, which is a key measure of long-term blood sugar management.
• Potential for Reduced Mealtime Insulin Doses: Because it helps manage post-meal glucose, some patients may find they need less mealtime insulin.
• Modest Weight Loss: It can help promote a feeling of fullness, which may lead to eating less and a slight reduction in body weight.

Clinical studies have shown that when added to insulin therapy, SymlinPen significantly improves A1c levels and reduces post-meal glucose excursions compared to insulin alone, providing a valuable option for fine-tuning diabetes care (AstraZeneca Pharmaceuticals LP, 2021).

How does SymlinPen work?

SymlinPen works by mimicking the actions of the natural hormone amylin. In a person without diabetes, the pancreas releases both insulin and amylin in response to a meal. While insulin helps cells absorb sugar from the blood, amylin helps to regulate the speed at which sugar enters the blood in the first place. Many people with diabetes either don’t produce amylin or don’t produce enough of it.

SymlinPen helps manage blood sugar by:

1. Slowing gastric emptying: Delays carbohydrate absorption, preventing rapid blood sugar spikes after meals.
2. Suppressing glucagon secretion: Blocks the release of stored sugar from the liver, reducing excess blood sugar.
3. Promoting satiety: Increases feelings of fullness, aiding in smaller meal portions and calorie reduction.

By performing these three actions, SymlinPen provides a multi-faceted approach to improving post-meal blood sugar control that complements the action of insulin.

SymlinPen side effects

The most significant risk associated with SymlinPen is a boxed warning, the FDA’s strongest warning, for the risk of severe hypoglycemia (dangerously low blood sugar). This risk is highest when SymlinPen is used with insulin.

Severe hypoglycemia risk is highest within three hours post-injection. When starting SymlinPen, reduce your usual mealtime insulin dose by 50% as instructed by your doctor. Frequent blood sugar monitoring, especially pre- and post-meals, is crucial to prevent low blood sugar.

The most common side effect of SymlinPen is nausea, especially when starting the medication. This is often mild to moderate and tends to decrease over time. Other common side effects may include:

• Decreased appetite
• Vomiting
• Headache
• Injection site reactions (redness, swelling)

Do not use SymlinPen if you have gastroparesis or hypoglycemia unawareness. Regular blood sugar testing is essential. Seek immediate medical attention for severe, unmanageable hypoglycemia symptoms like confusion, seizures, or loss of consciousness.

SymlinPen dosage

SymlinPen is an injectable medication that comes in a prefilled pen device. It is administered as a subcutaneous injection (an injection under the skin) into the abdomen or thigh.

Crucially, SymlinPen is injected immediately before major meals (meals containing at least 250 calories or 30 grams of carbohydrates). It is a separate injection from insulin and should never be mixed in the same syringe.

Your doctor will gradually increase your SymlinPen dose to minimize nausea. Close monitoring of blood glucose is essential, especially when starting or changing doses of SymlinPen or insulin. Mealtime insulin doses must be reduced at the start of SymlinPen, and your doctor will guide further adjustments.

Does SymlinPen have a generic version?

No, there is currently no generic version of SymlinPen (pramlintide acetate) available. However, international versions may exist in other markets. SymlinPen is a biologic medication, and a biosimilar (the equivalent of a generic) has not been approved by the FDA. Therefore, it is only available under the brand name SymlinPen.

Conclusion

For individuals with type 1 or type 2 diabetes who are already using mealtime insulin but still struggle with post-meal blood sugar control, SymlinPen offers a unique and effective adjunctive therapy. By mimicking the natural hormone amylin, it helps to smooth out glucose spikes, lower A1c, and may assist with weight management.

However, its use requires a significant commitment to safety. The risk of severe hypoglycemia is real and must be managed through careful insulin dose adjustments and frequent blood sugar monitoring. When used under the close guidance of a healthcare provider, SymlinPen can be a valuable addition to a comprehensive diabetes management plan, helping you achieve better control and take another positive step on your health journey.

References

1. AstraZeneca Pharmaceuticals LP. (2021). SYMLINPEN® (pramlintide acetate) injection Prescribing Information. U.S. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021342s031lbl.pdf
2. Mayo Clinic. (2024). Pramlintide (Subcutaneous Route). Retrieved from https://www.mayoclinic.org/drugs-supplements/pramlintide-subcutaneous-route/side-effects/drg-20065611